华特达因：公司及子公司目前没有长效胰岛素类似物产品的研发和合作

Group 1 - The core viewpoint of the article is that Huate Dain (华特达因) clarified that there is currently no research and collaboration on long-acting insulin analog products with its subsidiary Dain Pharmaceutical and the Chinese Academy of Medical Sciences [2] Group 2 - Investors inquired about the strategic cooperation agreement between Dain Pharmaceutical and the Chinese Academy of Medical Sciences, specifically regarding long-acting insulin analog products expected to enter clinical trials next year [2] - Huate Dain responded on the investor interaction platform, stating that there are no ongoing developments or collaborations related to the mentioned long-acting insulin analog products [2]